ProBiotix has entered into a material and exclusive long-term partnership agreement with Kemin China Group
ProBiotix Health plc (AQSE: PBX), a life sciences company developing probiotics to support cardiometabolic health, is pleased to announce an important new supply agreement in the Far East.
ProBiotix has entered into a material and exclusive long-term agreement with Kemin China Group, a business unit of Kemin Industries. The deal will allow KCG to sell the Company’s proprietary probiotic strain LPLDL® (Lactiplantibacillus plantarum LP LDL) as a cardiometabolic health supplement ingredient in China, Hong Kong, and Macau, with the opportunity to discuss expansion into other regions, driven by Kemin’s global commercial operations. ProBiotix will supply its raw materials in bulk to KCG, whereupon LPLDL® will be marketed and sold under a co-branding arrangement with the brand name of VasoNex™LPLDL®.
Over 330 million people in China are affected by cardiovascular health issues. The Chinese probiotic supplement retail market was valued in 2024 at $2.3 billion and is projected to reach $3.6 billion by 2028, a CAGR of 12.8%.
Steen Andersen, CEO of ProBiotix, commented:”With the huge prevalence of cardiovascular health issues in China, we are delighted to have secured this important, long-term collaboration with KCG, which should provide a significant and sustainable revenue stream to both companies. It provides the scope to expand our sales of LPLDL® in a key market for us with a well-established partner with a strong industry brand.
Dr. Zhilin Gan, President of Kemin China Group, commented: “We are excited to partner with ProBiotix on this important initiative to address the global challenge of cardiovascular health. Kemin has built a solid foundation of scientific expertise and business success in probiotics for digestive health and immune enhancement in both humans and animals. This collaboration aligns with our strategy to expand our probiotics portfolio. By combining ProBiotix’s cutting-edge probiotic research with Kemin China Group’s extensive market resources in China, we are committed to delivering innovative and effective cardiovascular health solutions to consumers.”
